Dysfunction of endothelial progenitor cells is associated with the type I IFN pathway in patients with polymyositis and dermatomyositis

Abstract

Objective. Alterations in phenotype and function of endothelial progenitor cells (EPCs) have been associated with poor vascular outcomes and impaired vascular repair in various conditions. Our hypothesis was that patients with PM and DM have dysregulation of EPCs driven by type I IFN and IL-18 similar to other autoimmune diseases.Methods. Quantification of circulating EPCs was performed by flow cytometry in patients with PM/DM and matched healthy controls. The ability of EPCs to differentiate into mature endothelial cells was investigated by light and fluorescence microscopy quantification in the presence or absence of PM/DM or control serum, neutralizing antibodies to type I IFN receptor or IL-18. Serum type I IFN activity was quantified by induction of type I IFN-inducible genes in HeLa cells. Circulating IL-18 concentrations were assessed by ELISA.Results. Circulating EPCs were significantly lower in PM/DM patients compared with controls. PM/DM EPCs displayed a decreased capacity to differentiate into mature endothelial cells and PM/DM serum significantly inhibited differentiation of control EPCs. This effect was reversed in the majority of samples with neutralizing antibodies to IL-18 or to type I IFN receptor or by a combination of these antibodies. Patients with associated impairments in EPC function had higher type I IFN serum activity.Conclusion. PM/DM is associated with dysregulation of EPC phenotype and function that may be attributed, at least in part, to aberrant IL-18 and type I IFN pathways. The implication of these vasculopathic findings for disease prognosis and complications remains to be determined.Key words: idiopathic inflammatory myopathies, IFN-regulated gene expression, interferon signature, IL-18, autoantibodies Rheumatology key messages. PM/DM is associated with dysregulation of endothelial progenitor cell phenotype and function. . Endothelial progenitor cell dysregulation in PM/DM may be attributed, in part, to IL-18 and type I IFN pathways. . Further research into the role of endothelial function in PM/DM may provide therapeutic insights.

Enhanced Inflammasome Activity in Systemic Lupus Erythematosus Is Mediated via Type I Interferon–Induced Up‐Regulation of Interferon Regulatory Factor 1

“…Gene expression was normalized to that of β‐actin, relative gene expression to normal controls was calculated by the comparative threshold cycle (C t ) method, and fold change was expressed as . IFN scores were calculated as previously described for IFI44 , MXA , and PRKR . Briefly, the mean fold change in samples from healthy control subjects was calculated, and the SLE IFN gene score was calculated as (SLE [gene] fold change – control [mean] fold change)/SD control.…”

Advances in Juvenile Dermatomyositis: Myositis Specific Antibodies Aid in Understanding Disease Heterogeneity

“…RNA-10a, a master regulator of proinflammatory cytokines via the NFkB pathway, also controls vascular system components (69). Studies of endothelial cells from adults with DM or PM showed a decrease in PM only, not in DM (70). Similarly, the number of endothelial precursor cells were normal in children with JDM (71), providing evidence that production of the endothelial cells is not the problem in JDM.…”

Endothelial Progenitor Cells: New Targets for Therapeutics for Inflammatory Conditions With High Cardiovascular Risk

“…Patients with systemic lupus erythematosus (SLE) have an elevated vascular risk due to an early onset of atherosclerosis, which appears to be independent of traditional CVD risk factors and associated with an altered interferon-α (IFNα) signaling pathway. It has been shown that IFNα alters the balance between endothelial cell apoptosis and vascular repair which is governed by both ECFCs and MACs ( 71 , 72 ). When focusing on CD34 + cells, it becomes clear that the majority of studies find decreased levels of circulating MACs in SLE patients ( 68 ).…”